Ray S. Mcdermott - Publications

Miliary TB - a retrospective cohort study of diagnostic and clinical features.

Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease

Published: August 01, 2026

EORTC 2238 DE-ESCALATE: Revisiting Intermittent Maximal Androgen Blockade in Metastatic Hormone-sensitive Prostate Cancer.

Journal: European urology

Published: June 08, 2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Journal: Lancet (London, England)

Published: March 23, 2026

National Trends in Early-Onset Colorectal Cancer: Incidence and Challenges in the Republic of Ireland.

Journal: JCO global oncology

Published: February 04, 2026

Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.

Journal: Endocrine-related cancer

Published: December 17, 2025

A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases.

Journal: Future oncology (London, England)

Published: November 28, 2025

Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 28, 2025

Fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab: Tumor-specific expansion cohorts in advanced malignancies.

Journal: Cancer

Published: November 04, 2025

Interrogating the immune landscape of microsatellite stable RAS-mutated colon cancer.

Journal: Molecular oncology

Published: September 19, 2025

CYCLONE 2: no impact on prostate cancer forecast.

Journal: The Lancet. Oncology

Published: August 12, 2025

Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E.

Journal: European urology oncology

Published: July 23, 2025

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 17, 2025